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Introduction
　A	 study	 group	 of	 the	 Ministry	 of	 Health,	
Labour	and	Welfare	(MHLW)	has	just	announced	
the	newest	2013	version	of	the	Guidelines	for	the	
Treatment	of	Chronic	Hepatitis	B1).	In	essence,	
the	 Guidelines	 specify	 drugs	 and	 treatment	
period	by	categorizing	patients	into	those	aged	
35	 years	 or	 older	 and	 those	 younger	 than	 35	
years.	 Recommended	 treatment	 regimens	 are	
classified	into	several	types	based	on	presence	
or	absence	of	the	hepatitis	B	e	antigen	(eAg)	or	
hepatitis	B	DNA	(HBV-DNA),	and	the	alanine	
transaminase	 (ALT)	 level	 prior	 to	 treatment.	
According	to	the	Guidelines,	therapeutic	agents	
are	selected	from	2	types,	pegylated	interferon	
(peginterferon)	alfa-2a	and	entecavir,	which	is	a	
nucleoside	analog	(NA)	preparation.	The	use	of	
the	former	drug	is	limited	to	48	weeks,	while	no	
limitation	is	specified	for	the	latter	drug.
　The	purpose	of	treatment	of	chronic	hepatitis	
B	 is	 inhibition	 of	 disease	 progression	 and	
prevention	 of	 cancer.	 Specifically,	 treatment	
is	 intended	 to	 achieve	 seroconversion	 of	 eAg	
so	 that	 hepatitis	 B	 surface	 antigen	 (HBsAg)	
would	 eventually	 turn	 negative	 through	 the	
antiviral	 and	 immunostimulatory	 actions	 of	
peginterferon	alfa-2a	in	the	long	term2).	In	the	
short	term,	treatment	aims	to	obtain	negative	
serostatus	 of	 HBV-DNA	 through	 the	 potent	
inhibitory	effect	of	entecavir	on	the	replication	
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of	HBV-DNA3-5).	The	Guidelines	were	developed	
to	adjust	the	treatment	according	to	the	clinical	
background	of	each	patient,	thereby	obtaining	
the	therapeutic	effect	more	efficiently.
　In	 actual	 treatment,	 it	 often	 takes	 1	 to	 2	
years	 to	 evaluate	 the	 therapeutic	 effect	 of	
peginterferon	 alfa-2a.	 In	 contrast,	 entecavir	
produces	 its	 effect	 quickly.	 In	many	 patients,	
serum	HBV-DNA	becomes	negative	after	a	few	
months	of	treatment.	However,	a	small	number	
of	 patients	 develop	 resistance	 to	 treatment	
with	entecavir.	 Issues	related	to	entecavir	 for	
future	research	include	resistance	to	treatment	
as	well	as	the	timing	of	stopping	treatment.
　According	 to	 the	Guidelines,	 candidates	 for	
treatment	with	 entecavir	 are	 patients	with	 a	
high	viral	load,	those	with	abnormal	ALT	and	
those	 of	 advanced	 age	 for	 whom	 histological	
progression	 is	 expected.	 Overseas	 guidelines	
are	 composed	 of	 largely	 the	 same	 criteria6-8).	
The	 Guidelines	 issued	 by	 the	 MHLW	 Study	
Group	 specify	 that	 patients	 with	 HBV-DNA	
of　≧4	log	copies/mL	and	ALT	of	≧31	IU/L	
undergo	 treatment	with	 entecavir,	 regardless	
of	 the	 presence	 or	 absence	 of	 eAg.	 In	 actual	
clinical	practice,	a	large	proportion	of	patients	
are	35	years	of	age	or	older	and	eAg	negative,	
which	 means	 that	 entecavir	 is	 the	 first-line	
therapy	for	most	patients.
　The	 ultimate	 goal	 of	 treatment	 for	 chronic	
hepatitis	B	is	to	achieve	remission	and	prevent	
cancer	 through	 achieving	 seronegativity	 of	
HBsAg,	which	means	elimination	of	the	virus.	
In	the	short	term,	treatment	aims	to	normalize	
ALT,	convert	eAg	to	seronegative	or	achieve	
seroconversion	to	e	antibody	(eAb)	and	obtain	
negative	 HBV-DNA	 serostatus.	 Currently,	 no	
clear	conclusion	has	been	reached	concerning	
the	evaluating	of	 the	therapeutic	effect	of	 the	
above-mentioned	 drugs	 with	 respect	 to	 long-
term	 prognosis	 and	 the	 necessity	 of	 using	
combination	therapy	with	these	drugs.
　In	 the	 present	 study,	 we	 serially	 and	
quantitatively	 measured	 HBsAg	 in	 patients	
with	 chronic	 hepatitis	 B	 treated	 with	 NAs	
after	the	start	of	treatment,	and	examined	the	
significance	of	treatment	with	NAs	for	the	long-
term	prognosis	of	the	disease.
Materials and methods
Subjects
　This	study	included	18	patients	with	chronic	
hepatitis	 B	 who	 were	 treated	 with	 various	
nucleoside	 analogs（NA）.	 In	 each	 patient,	
HBsAg	was	measured	after	starting	treatment	
with	serial	observation	at	least	once	a	year	and,	
ALT,	 HBV-DNA	 levels,	 eAg	 /eAb,	 hepatitis	
B	 virus	 core-related	 antigen（HBcrAg）and	
HBV	genotype	also	were	evaluated.
Quantification of HBsAg
　HBsAg	 was	 quantified	 using	 a	
ARCHTECT・HBsAg	 QT	 kit（Abbot	 Japan	
Co.	Ltd.,	Chiba,	Japan）.	The	result	was	were	
expressed	 as	 IU/ml.	 The	 value	 of	more	 than	
0.05	IU/ml	was	considered	positive.	
Quantification of HBV-DNA
　Serum	 HBV-DNA	 was	 quantified	 using	
a	 TMA	 kit	 (Chugai	 Diagnostic	 Science	 Co.	
Ltd.,	Tokyo,	Japan)	,	at	a	first.	The	result	was	
were	 expressed	 as	 log	 genome	 equivalent	
(LGE)	 /	ml.	 The	 value	 of	 less	 than	 3.7	 LGE/
mL	was	 considered	 as	 an	 undetectable	 level.	
Subsequently	HBV	DNA	was	quantified	using	
a	 COBAS	 AmpliPrep-COBAS	 TaqMan	 HBV	
test	(Roche,	Branchburg,	NJ,	USA).	The	result	
was	 expressed	 as	 a	 log	 copy	 number	 /	 ml.	
The	 value	 of	 less	 than	 2.1	 log	 copy/ml	 was	
considered	as	an	undetectable	level.	
Determination of serum eAg and eAb
　Serum	 eAg	 and	 eAb	 were	 determined	 by	
enzyme-linked	 immunosorbent	 assay.	 	 The	
result	of	eAg	was	expressed	as	cut	off	 index.	
The	 value	 more	 than	 2.0	 was	 considered	
positive.	The	 result	 of	 eAb	was	expressed	as	
%inhibition.	 The	 value	 more	 than	 50%	 was	
considered	positive.	
Quanrtification of HBcrAg
　Serum	 HBcrAg	 was	 quantified	 using	 a	
Lumipulse	kit（Fujirebio	Inc.,	Tokyo,	Japan）.	
The	result	was	expressed	as	a	log	unit	/	ml.	The	
value	more	than	3.0	was	considered	positive.	
HBV genotyping 
　HBV	 genotyping	 were	 performed	 using	
Imunis	 kit	 (Institute	 of	 Immunology	 Co.	 Ltd.,	
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Tokyo,	Japan).
Determination of amino acid substitution the 
reverse transcriptase domain of polymerase gene	
　Determination	 of	 amino	 acid	 substitution	 in	
the	 rt	 domain	 of	 polymerase	 gene	 which	 is	
resistant	 to	 lamivudine	 was	 performed	 using	
Inno-LiPA	HBV	DR	Version2	Plus	kit	(Medical	
and	Biological	Laboratories	Co	Ltd.,	Ina,	Japan	).
Statistical analysis
　Statistical	 analysis	 was	 performed	 using	
SPSS	20.0J	 for	Windows	 (SPSS	 Inc.,	 IL,	USA).	
Student's	 t-test	 and	 Pearson’s	 correlation	
coefficient	 were	 employed	 to	 determine	
significant	differences,	and	p	values	of	less	than	
5%	were	considered	significant.	
Ethical considerations
　The	present	study	conformed	to	the	guidelines	
of	 epidemiological	 studies	 devised	 by	 the	
Ministry	of	Health,	Labor	and	Welfare,	 Japan,	
to	prevent	leakage	of	personal	information,	and	
were	 conducted	 to	 for	 the	 purpose	 of	 social	
profit.	
Results
Background of the study patients
　This	study	comprised	a	total	of	18	patients	(13	
males,	5	females;	mean	age,	57.3	years;	median	
age,	 60	 years;	 mean	 observation	 period,	 59.8	
months;	median	observation	period,	55	months).	
The	background	of	the	patients	is	summarized	
in	Table	1.	Three	patients	were	eAg	positive,	
2	 were	 negative	 for	 both	 eAg	 and	 eAb,	 and	
13	 were	 eAb	 positive.	 The	 genotype	 was	 B	
in	10	patients	and	C	 in	8	patients.	Treatment	
was	started	with	lamivudine	in	7	patients	and	
was	continued	 in	2.	Three	of	 those	7	patients	
had	viral	breakthrough	due	to	emergence	of	a	
resistant	strain,	and	adefovir	was	added.	In	the	
remaining	2	patients,	lamivudine	was	switched	
to	 entecavir.	 Treatment	 was	 started	 with	
entecavir	 in	11	patients	and	was	continued	in	
all	11.	At	the	completion	of	observation,	HBV-
DNA	was	 negative	 in	 13	 patients	 and	 signal	
positive	in	5,	indicating	a	clear	decrease.	ALT	
was	stable	in	all	patients.	The	clinical	course	was	
favorable	in	all	patients	except	1	with	genotype	
C,	 who	 was	 receiving	 continuous	 treatment	
with	 lamivudine	and	developed	hepatocellular	
carcinoma	(HCC).
Correlation of HBsAg with HBV-DNA, HBcrAg and 
ALT before treatment
　The	relationships	among	HBsAg,	HBV-DNA	
and	ALT	 in	 8	 patients	 for	whom	 comparison	
was	 possible	 before	 the	 treatment	 with	 NAs	
Table 1．Patients with hepatitis B who were treated with nucleoside analogs
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are	 presented	 in	 Figures	 1	 through	 4.	 A	
significant	positive	correlation	between	HBsAg	
and	HBV-DNA	was	observed	when	HBV-DNA	
was	expressed	in	units	of	logarithmic	genome	
equivalents	(LGE)/mL,	and	a	tendency	toward	
positive	correlation	was	noted	when	HBV-DNA	
was	 expressed	 in	 log	 copies/mL.	 A	 similar	
tendency	 toward	 positive	 correlation	 was	
observed	between	HBV-DNA	and	HBcrAg.	No	
correlation	was	found	between	HBV-DNA	and	
ALT.
Comparison of backgrounds before treatment 
according to genotype
　The	background	of	the	8	patients	for	whom	
comparison	 was	 possible	 before	 initiation	
of	 treatment	 with	 NAs	 was	 examined	 by	
genotype	(Table	2).	Five	patients	had	genotype	
B	and	3	patients	had	genotype	C.	No	difference	
Figure 1．Correlation between HBsAg 
concentration and HBV-DNA（LEG/mL）
before the nucleoside analog treatment
Figure 2．Correlation between HBsAg 
concentration and HBV-DNA（Log copy/
mL） before the nucleoside analog 
treatment
Figure 3．Correlation between HBsAg 
concentration and HBcrAg before the 
nucleoside analog treatment
Figure 4．Correlation between HBsAg 
concentration and ALT before the 
nucleoside analog treatment
Table 2．Age and labolatory data at the 
start of the nucleoside analog treatment 
according to a genotype
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was	observed	in	age	and	HBsAg	between	the	
genotypes,	 while	 HBcrAg	 was	 significantly	
higher	 in	 patients	 with	 genotype	 C.	 ALT	
showed	a	tendency	toward	increase	in	patients	
with	genotype	C.
Comparison of various markers in patients between 
initiation of treatment and endpoint of observation 
　Changes	in	HBV-DNA,	HBsAg	and	HBcrAg	
in	 8	 patients	 for	 whom	 comparison	 was	
possible	 between	 these	 variables	 at	 the	 start	
of	treatment	with	NAs	and	at	the	time	of	the	
last	 observation	 are	 presented	 in	 Table	 3.	
Treatment	with	lamivudine	was	continued	in	2	
patients,	adefovir	was	added	to	lamivudine	due	
to	emergence	of	a	resistant	strain	in	1	patient,	
and	treatment	with	entecavir	was	continued	in	
5	patients.	HBV-DNA	was	high	 in	all	patients	
(5.7	to	7.3	LGE/mL	or	5.8	to	>	8.8	 log	copies/
mL)	 at	 the	 start	 of	 treatment	 and	 >2.1	 log	
copies/mL	 in	 all	 patients	 at	 the	 time	 of	 the	
last	observation,	indicating	a	marked	decrease.	
However,	 HBsAg	 showed	 a	 clear	 decrease	
only	in	3	patients,	was	largely	unchanged	in	4	
patients,	and	was	clearly	increased	in	1	patient,	
who	 developed	HCC.	HBsAg	 remained	 above	
1,000	IU/mL	in	5	patients,	and	>2,000	IU/mL	in	
3	of	the	5	patients.	Seven	out	of	8	patients	were	
HBcrAg	positive	at	the	start	of	treatment,	and	
HBcrAg	 became	 negative	 only	 in	 2	 patients	
at	the	time	of	the	 last	observation.	The	other	
5	 patients	 continued	 to	 be	 HBcrAg	 positive,	
although	 the	 amount	 of	 antigen	 decreased.	
The	 patient	 whose	 HBsAg	 increased	 and	
who	developed	HCC	continued	to	be	HBcrAg	
positive.	 The	 onset	 of	 cancer	was	 85	months	
after	the	start	of	treatment	with	lamivudine.
Subsequent changes in HBsAg concentration after 
the start of nucleoside analog treatment
　The	 changes	 in	 HBsAg	 over	 time	 in	 the	
7	 patients	 who	 started	 the	 treatment	 with	
lamivudine	are	shown	 in	Figure	5.	The	mean	
duration	 of	 observation	 was	 93.4	 months	
(median,	 88	months).	The	 rates	 of	 increase	or	
decrease	in	HBsAg	at	the	start	of	treatment	are	
presented.	In	one	of	the	patients	who	continued	
to	 be	 treated	 with	 lamivudine	 only,	 HBsAg	
started	to	increase	1	year	after	the	start	of	the	
treatment	and	was	4.6	times	the	starting	level	
after	2	years.	Then,	HBsAg	gradually	decreased,	
but	 the	 patient	 developed	HCC	 7	 years	 after	
the	start,	when	HBsAg	was	2.6	times	the	level	
at	the	start	of	treatment.	In	the	other	patient,	
who	was	continuously	treated	with	lamivudine	
only,	HBsAg	increased	to	1.8	times	the	level	at	
the	start	of	the	treatment	after	2	years,	became	
decreased	thereafter,	and	was	below	the	level	
at	 the	 start	 and	 further	 decreased	 gradually	
from	3	to	8	years	after	the	start.	In	all	3	patients	
who	received	the	addition	of	adefovir	and	the	
2	patients	for	whom	lamivudine	was	switched	
to	entecavir,	HBsAg	was	below	the	level	at	the	
start	of	the	treatment	and	gradually	decreased	
from	3	years	after	the	start.
　The	 changes	 in	 HBsAg	 over	 time	 in	 the	
11	 patients	 who	 started	 the	 treatment	 with	
entecavir	 are	 shown	 in	 Figure	 6.	 The	 mean	
duration	 of	 the	 observation	 period	 was	 38.5	
months	(median,	36	months).	As	with	the	patients	
who	started	the	treatment	with	lamivudine,	the	
rates	 of	 increase	 or	 decrease	 from	HBsAg	 at	
Table 3．Status of HBV-DNA, HBsAg and HBcrAg concentration at the start and endpoint 
of observation in patients treated with various nucleoside analogs
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Figure 5．Subsequent changes of HBsAg concentration in patients in whom the nucleoside 
analog treatment was started with lamivudine. A value of HBsAg at the start of treatment 
is defined to be 1.  Red lines present patients in whom lamivudine was continued, blue 
lines present those in whom adefovir was added because of viral breakthough, and black 
lines present those in whom lamivudine was switched to entecavir.  *Asterisk indicates 
the patient who developed HCC.
Figure 6．Subsequent changes of HBsAg concentration in patients in whom the nucleoside 
analog treatment was started with entecavir. A value of HBsAg at the start of treatment 
is defined to be 1.  Red lines present patients who were positive for HBeAg  and black 
lines present patients who were positive for HBeAb at the start of treatment respectively. 
*Asterisk indicates the patient who lost  HBeAg.
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the	start	of	the	treatment	are	presented.	In	one	
of	the	3	eAg	positive	patients,	HBsAg	increased	
after	 the	 start	 of	 the	 treatment,	 reached	 3.4	
times	the	starting	level	2	years	later,	and	was	
still	3.0	times	the	starting	level	at	3	years	after	
the	start.	In	the	other	2	eAg	positive	patients,	
HBsAg	gradually	decreased	to	below	the	level	
at	the	start	of	the	treatment,	at	1	year	after	the	
start.	 In	 some	 of	 the	 8	 eAb	positive	 patients,	
HBsAg	was	higher	than	the	level	at	the	start	of	
the	treatment	even	3	years	after	the	start	and	
thereafter.
Discussion
　The	 therapeutic	 methods	 for	 chronic	
hepatitis	B	 that	have	been	 improved	 through	
various	transitions	have	just	been	summarized	
in	the	newest	Guidelines	from	the	MHLW.	The	
short-term	therapeutic	goals	are	prevention	of	
cancer	and	inhibition	of	fibrosis	by	the	strong	
inhibitory	 action	 of	NAs	 on	 the	 replication	 of	
HBV-DNA9,10).	In	the	present	study,	HBV-DNA	
decreased	 down	 to	 the	 undetectable	 level	 or	
less	at	the	time	of	the	last	observation	in	all	18	
study	patients.	The	clinical	 course	was	stable	
in	all	patients	except	1	who	developed	HCC.	In	
that	patient,	HBsAg	clearly	increased	from	the	
level	at	the	start	of	treatment,	and	HBcrAg	also	
continued	to	be	positive.
　Moreover,	 in	5	 (including	 the	above	patient	
who	developed	HCC)	out	of	the	8	patients	for	
whom	comparison	of	variables	before	and	after	
the	treatment	was	possible,	HBsAg	clearly	did	
not	 decrease	 and	 remained	 >1,000	 IU/mL	 at	
the	time	of	the	last	observation.	Patients	with	
HBsAg	 levels	 of	 1000	 IU/mL	 or	 higher	 have	
been	 reported	 to	 be	 at	 high	 risk	 for	 cancer	
and	therefore	should	be	carefully	observed	for	
possible	development	of	cancer	in	the	future11,12).	
Before	 the	 start	 of	 the	 treatment	 with	 NAs,	
a	 positive	 correlation	 or	 a	 tendency	 toward	
correlation	 was	 observed	 between	 HBsAg	
and	 HBV-DNA.	 However,	 while	 HBV-DNA	
decreased	rapidly	after	the	start	of	treatment,	
HBsAg	 increased,	 remained	 unchanged	 or	
decreased,	showing	various	patterns13).
　In	 the	 patients	 for	 whom	 treatment	 was	
started	with	lamivudine	and	adefovir	was	added	
due	to	emergence	of	a	resistant	strain,	decrease	
in	HBsAg	was	most	rapid	and	prominent.	All	
patients	for	whom	treatment	was	started	with	
entecavir	 remained	 on	 the	 same	 treatment.	
Among	them,	1	out	of	3	eAg	positive	patients	
showed	an	 increase	 in	HBsAg.	 In	contrast,	 in	
another	 eAg	 positive	 patient,	 HBsAg	 rapidly	
decreased	 after	 the	 start	 of	 treatment	 and	
eAg	 became	 negative;	 this	 suggests	 that	 the	
disappearance	of	eAg	or	a	continued	decrease	
in	 HBV-DNA	 can	 be	 expected	 if	 a	 clear	
decrease	in	HBsAg	is	observed	after	the	start	
of	 treatment	 in	 eAg	 positive	 patients14,15).	 In	
the	other	patients,	a	clear	 tendency	 toward	a	
decrease	 in	 HBsAg	 was	 not	 noted,	 probably	
due	to	the	short	observation	period.	Based	on	
these	 results,	 when	 the	 long-term	 goal	 is	 to	
achieve	negative	HBsAg,	some	patients	do	not	
easily	benefit	 from	monotherapy	with	an	NA,	
specifically	 entecavir.	 Therefore,	 concomitant	
use	of	peginterferon	alfa-2a	or	sequential	therapy	
in	which	 an	NA	 is	 switched	 to	 peginterferon	
alfa-2a	 should	 be	 considered	 in	 the	 future.	
Nevertheless,	 no	 sufficient	 evidence	 exists	 at	
present	for	improvement	in	therapeutic	efficacy	
by	either	of	the	above	methods1,16).
　A	positive	correlation	was	observed	between	
HBsAg	 and	 HBcrAg	 before	 the	 start	 of	
treatment;	after	the	start	of	treatment,	HBcrAg	
did	 not	 become	 negative	 in	 patients	 whose	
HBsAg	 clearly	 did	 not	 decrease.	 HBcrAg	
is	 known	 to	 reflect	 the	 amount	 of	 covalently	
closed	 circular	 DNA	 (cccDNA),	 a	 replicative	
intermediate	 of	 intrahepatic	 HBV17)	 .	 The	
absence	of	a	decrease	in	HBsAg	is	considered	
to	indicate	that	the	HBV	replication	in	the	liver	
has	not	been	stopped,	regardless	of	the	serum	
HBV-DNA	level.	For	this	reason,	it	is	necessary	
to	 recognize	 the	 risk	 for	 the	 development	 of	
liver	cancer	 in	patients	without	a	decrease	 in	
HBsAg.	 In	 particular,	 patients	with	 genotype	
C	who	 have	 a	 significantly	 increased	 level	 of	
HBcrAg	require	close	observation.
　In	 the	 present	 study,	 treatment	 with	 NAs	
clearly	decreased	the	serum	HBV-DNA	level	in	
patients	with	chronic	hepatitis	B,	but	was	not	
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sufficiently	 effective	 in	 reducing	 HBsAg.	 One	
of	 the	 patients	 treated	 with	 NAs	 developed	
cancer.	 Although	 many	 of	 the	 patients	 were	
eAb	positive,	HBsAg	remained	high	after	 the	
treatmalest	with	NAs	in	half	of	these	patients.	
This	suggests	that	seroconversion	to	eAb	does	
not	contribute	to	a	reduction	in	cancer	risk.
　We	 therefore	 speculate	 that	 serial	
quantitative	measurement	of	HBsAg	in	patients	
being	treated	with	NAs	is	useful	for	monitoring	
the	 efficacy	 of	 this	 treatment.	 Moreover,	 we	
consider	 that	 such	 measurement	 should	 be	
used	more	frequently	in	the	future	for	selecting	
which	 untreated	 chronic	 hepatitis	 B	 patients	
should	receive	treatments	with	NAs.	
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9Clinical	significance	of	serial	quantitative	measurement	of	hepatitis	B	surface	antigen
和文要旨
　Nucleoside	analog（NA）投与を行った B 型慢性肝炎 18 例（男性 13 例、女性 5 例、観察期間中央値
55 ヵ月）を対象にした。治療前後の比較が可能であった 8例では、治療前のHBsAg 量と HBV-DNA量お
よびHBcrAg 量には相関傾向がみとめられた。治療開始時に高値を示したHBV-DNA量は、全例検出感度
以下に著減した。しかし、HBsAg 量が減少したのは 3 例のみで、他の 4 例は不変、1 例は増加した。
HBsAg 量増加の 1例ではHBcrAg 量の減少も不十分で、治療開始 85 ヵ月後にHCCの発生をみた。HBsAg
量非減少例では、発がんのリスクを認識しておく必要があると考えられた。全 18 例でみても、NA治療は
B型慢性肝炎患者の血中HBV-DNA量を明らかに減少させたが、HBsAg 量の減少効果は不十分であった。
今後 B 型慢性肝炎の治療は HBsAg 量の減少を目指し、NA と peginterferon	alpha-2a の併用あるいは
sequential	 therapy も考慮されるべきと考えられる。NA治療例におけるHBsAg 量の経時的測定は、NA
治療中の治療効果把握のモニタリングに有用であると考えられる。
キーワード：HBs 抗原、HBe 抗原・抗体、HBV-DNA、HB コア関連抗原、核酸アナログ製剤
